Glenmark Pharmaceuticals Ltd, founded in 1977 by Gracias Saldanha and headquartered in Mumbai, India, is a global, research-driven pharmaceutical company. Initially focusing on generic drugs and active pharmaceutical ingredients, Glenmark has expanded its reach to over 80 countries, offering a diverse portfolio that includes branded, generic, and over-the-counter (OTC) medications. The company specializes in key therapeutic areas such as respiratory (asthma and COPD treatments), dermatology, and oncology. With four research and development centers and ten manufacturing facilities across five continents, Glenmark is dedicated to innovation, with a strong pipeline of new chemical entities (NCEs) and biosimilars. In January 2024, the company formed Ichnos Glenmark Innovation (IGI) in collaboration with its subsidiary, Ichnos Sciences Inc., to advance the development of innovative cancer treatments, particularly for multiple myeloma, acute myeloid leukemia, and solid tumors.
Glenmark Pharmaceuticals Reports Over 200% Surge in Q1 FY25 Net Profit, Revenue Up 7%
- Net Profit: Glenmark Pharmaceuticals Ltd’s net profit for Q1 FY25 surged to ₹340.2 crore, up from ₹37.7 crore in Q1 FY24.
- Profit Before Exceptional Items and Taxes: Increased to ₹462 crore, compared to ₹203 crore a year ago, despite a ₹52.02 crore one-time charge for repairs.
- Revenue from Operations: Rose by 6.9% to ₹3,244.2 crore from ₹3,036 crore in the previous fiscal’s Q1.
- EBITDA: Jumped 34.5% to ₹588.3 crore, with an EBITDA margin improving to 18.1% from 14.4% in the corresponding period last year.
- Formulation Sales in India: Grew by 11.9%, reaching ₹1,196.2 crore compared to ₹1,069.3 crore in Q1 FY24.
Shareholdings Patterns of Glenmark Pharmaceuticals Ltd
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | |
| Promoters + | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% |
| FIIs + | 25.51% | 24.79% | 23.71% | 21.38% | 20.98% |
| DIIs + | 9.10% | 10.31% | 10.92% | 13.36% | 13.93% |
| Government + | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public + | 18.70% | 18.21% | 18.70% | 18.58% | 18.42% |
| No. of Shareholders | 2,36,908 | 2,32,685 | 2,09,931 | 1,99,451 | 1,92,630 |
The shareholding patterns for Glenmark Pharmaceuticals Ltd from June 2023 to June 2024 reveal a stable ownership structure among key stakeholders. Promoters have consistently held 46.65% of the shares throughout the year. Foreign Institutional Investors (FIIs) have gradually reduced their stake from 25.51% to 20.98%, while Domestic Institutional Investors (DIIs) have increased their holding from 9.10% to 13.93%. Government ownership has remained steady at 0.04%, and public shareholding has slightly decreased from 18.70% to 18.42%. Additionally, the total number of shareholders has decreased from 236,908 to 192,630, indicating a reduction in the shareholder base over the year.
How to Buy Glenmark Pharmaceuticals Ltd Shares in India?
Below are the trading platforms that you can use to purchase Glenmark Pharmaceuticals Ltd shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
Glenmark Pharmaceuticals Ltd Share Price Prediction: 2024 – 2030
Glenmark Pharmaceuticals Ltd Share Price Target 2024
| When | Maximum Price | Minimum Price |
| August 2024 | 1,583.05 | 1,376.57 |
| September 2024 | 1,646.38 | 1,431.63 |
| October 2024 | 1,614.09 | 1,403.56 |
| November 2024 | 1,678.66 | 1,459.70 |
| December 2024 | 1,695.44 | 1,474.30 |
As we approach August 2024, the maximum price for Glenmark Pharmaceuticals Ltd is expected to reach ₹1,583.05, with a minimum price of ₹1,376.57. Moving into September 2024, the maximum price is projected to be ₹1,646.38, while the minimum may touch ₹1,431.63. In October 2024, Glenmark Pharmaceuticals Ltd is anticipated to see a maximum price of ₹1,614.09 and a minimum of ₹1,403.56. For November 2024, the maximum price could rise to ₹1,678.66, with a minimum price of ₹1,459.70. As we close the year in December 2024, Glenmark Pharmaceuticals Ltd is forecasted to have a maximum price of ₹1,695.44 and a minimum of ₹1,474.30.
Glenmark Pharmaceuticals Ltd Share Price Target 2025
| When | Maximum Price | Minimum Price |
| January 2025 | 1,712.40 | 1,317.23 |
| February 2025 | 1,729.70 | 1,330.54 |
| March 2025 | 1,766.02 | 1,358.48 |
| April 2025 | 1,748.53 | 1,345.03 |
| May 2025 | 1,697.61 | 1,305.85 |
| June 2025 | 1,774.00 | 1,364.61 |
| July 2025 | 1,739.21 | 1,337.86 |
| August 2025 | 1,793.00 | 1,379.23 |
| September 2025 | 1,814.52 | 1,395.78 |
| October 2025 | 1,861.70 | 1,432.08 |
| November 2025 | 1,908.24 | 1,467.88 |
| December 2025 | 1,994.11 | 1,533.93 |
As we step into January 2025, Glenmark Pharmaceuticals Ltd’s share price is projected to reach a maximum of ₹1,712.40 and a minimum of ₹1,317.23. Moving through the year, the prices are expected to rise, with February reaching ₹1,729.70 at its peak and ₹1,330.54 at its lowest. By March, the prices should climb further, with a maximum of ₹1,766.02 and a minimum of ₹1,358.48. April and May might see a slight dip, but the trend should recover in June with a peak at ₹1,774.00. As we step into the second half of 2025, the prices are expected to continue their upward momentum, culminating in December 2025, with Glenmark Pharmaceuticals Ltd potentially hitting a maximum of ₹1,994.11 and a minimum of ₹1,533.93.
Glenmark Pharmaceuticals Ltd Share Price Prediction 2026
| When | Maximum Price | Minimum Price |
| January 2026 | 2,053.93 | 1,579.95 |
| February 2026 | 2,002.59 | 1,540.45 |
| March 2026 | 2,042.64 | 1,571.26 |
| April 2026 | 2,084.32 | 1,603.33 |
| May 2026 | 2,063.69 | 1,587.45 |
| June 2026 | 2,115.28 | 1,627.14 |
| July 2026 | 2,073.80 | 1,595.23 |
| August 2026 | 2,137.94 | 1,644.57 |
| September 2026 | 2,180.70 | 1,677.46 |
| October 2026 | 2,237.40 | 1,721.08 |
| November 2026 | 2,293.33 | 1,764.10 |
| December 2026 | 2,350.67 | 1,808.21 |
Glenmark Pharmaceuticals Ltd Share Price Target 2027
| When | Maximum Price | Minimum Price |
| January 2027 | 2,374.17 | 1,826.29 |
| February 2027 | 2,435.05 | 1,873.12 |
| March 2027 | 2,530.02 | 1,946.17 |
| April 2027 | 2,480.41 | 1,908.01 |
| May 2027 | 2,408.16 | 1,852.43 |
| June 2027 | 2,516.53 | 1,935.79 |
| July 2027 | 2,467.19 | 1,897.84 |
| August 2027 | 2,543.49 | 1,956.53 |
| September 2027 | 2,632.51 | 2,025.01 |
| October 2027 | 2,700.96 | 2,077.66 |
| November 2027 | 2,768.48 | 2,129.60 |
| December 2027 | 2,837.70 | 2,182.84 |
Glenmark Pharmaceuticals Ltd Share Price Target 2028
| When | Maximum Price | Minimum Price |
| January 2028 | 2,894.45 | 2,226.50 |
| February 2028 | 2,968.67 | 2,283.59 |
| March 2028 | 3,084.44 | 2,372.65 |
| April 2028 | 3,023.97 | 2,326.13 |
| May 2028 | 2,935.89 | 2,258.38 |
| June 2028 | 3,068.00 | 2,360.00 |
| July 2028 | 3,007.85 | 2,313.73 |
| August 2028 | 3,100.87 | 2,385.29 |
| September 2028 | 3,209.40 | 2,468.77 |
| October 2028 | 3,292.85 | 2,532.96 |
| November 2028 | 3,375.17 | 2,596.28 |
| December 2028 | 3,459.55 | 2,661.19 |
Glenmark Pharmaceuticals Ltd Share Price Prediction 2029
| When | Maximum Price | Minimum Price |
| January 2029 | 3,528.74 | 2,714.41 |
| February 2029 | 3,619.22 | 2,784.02 |
| March 2029 | 3,760.37 | 2,892.59 |
| April 2029 | 3,686.64 | 2,835.87 |
| May 2029 | 3,579.26 | 2,753.28 |
| June 2029 | 3,740.33 | 2,877.17 |
| July 2029 | 3,666.99 | 2,820.76 |
| August 2029 | 3,780.40 | 2,908.00 |
| September 2029 | 3,912.71 | 3,009.78 |
| October 2029 | 4,014.44 | 3,088.03 |
| November 2029 | 4,114.80 | 3,165.23 |
| December 2029 | 4,217.67 | 3,244.36 |
Glenmark Pharmaceuticals Ltd Share Price Target 2030
| When | Maximum Price | Minimum Price |
| January 2030 | 4,302.03 | 3,309.25 |
| February 2030 | 4,412.34 | 3,394.10 |
| March 2030 | 4,584.42 | 3,526.47 |
| April 2030 | 4,494.53 | 3,457.33 |
| May 2030 | 4,363.62 | 3,356.63 |
| June 2030 | 4,559.98 | 3,507.68 |
| July 2030 | 4,470.57 | 3,438.90 |
| August 2030 | 4,608.83 | 3,545.26 |
| September 2030 | 4,770.14 | 3,669.34 |
| October 2030 | 4,894.17 | 3,764.74 |
| November 2030 | 5,016.52 | 3,858.86 |
| December 2030 | 5,141.93 | 3,955.33 |
As we step into January 2030, Glenmark Pharmaceuticals Ltd’s price is projected to range from ₹4,302.03 to ₹3,309.25. By mid-year, June 2030 may see prices between ₹4,559.98 and ₹3,507.68. Moving into December 2030, the price is expected to reach a maximum of ₹5,141.93 and a minimum of ₹3,955.33.
Glenmark Pharmaceuticals Ltd Financial Condition: Last 5 Years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 12,021 |
| Expenses + | 8,942 | 8,860 | 9,978 | 10,712 | 10,618 | 10,675 |
| Operating Profit | 1,699 | 2,084 | 2,327 | 2,278 | 1,195 | 1,346 |
| OPM % | 16% | 19% | 19% | 18% | 10% | 11% |
| Other Income + | 191 | 95 | -101 | -449 | 336 | 265 |
| Interest | 377 | 353 | 298 | 350 | 516 | 444 |
| Depreciation | 417 | 444 | 487 | 611 | 582 | 558 |
| Profit before tax | 1,096 | 1,382 | 1,441 | 868 | 434 | 609 |
| Tax % | 29% | 30% | 31% | 57% | 430% | |
| Net Profit + | 776 | 970 | 994 | 377 | -1,434 | -1,266 |
| EPS in Rs | 27.5 | 34.38 | 33.37 | 10.53 | -53.22 | -46.46 |
| Dividend Payout % | 9% | 7% | 7% | 24% | -5% |
Over the past five years, Glenmark Pharmaceuticals Ltd has experienced notable financial fluctuations. Sales initially increased from ₹10,641 crore in March 2020 to ₹12,990 crore in March 2023 but then declined to ₹11,813 crore in March 2024. Expenses have risen steadily, peaking at ₹10,712 crore in March 2023 before slightly declining to ₹10,618 crore in March 2024. Operating profit has varied significantly, from a high of ₹2,327 crore in March 2022 to ₹1,195 crore in March 2024, with a decreasing operating profit margin. Other income shifted from positive ₹191 crore in March 2020 to negative ₹449 crore in March 2023 before recovering to ₹336 crore in March 2024. Interest expenses and depreciation have increased, while profit before tax showed high volatility, dropping to ₹434 crore in March 2024. The tax rate reached an exceptionally high 430% in March 2024, leading to a net profit decline from ₹776 crore in March 2020 to a loss of ₹1,434 crore in March 2024. Consequently, EPS deteriorated to negative ₹53.22 in March 2024, and the dividend payout turned negative. Overall, these figures highlight significant challenges for Glenmark Pharmaceuticals Ltd, including declining profitability and financial strain.
FAQs
What is the current market capitalization of Glenmark Pharmaceuticals Ltd?
As of August 17th, 2024, the market cap is quite strong, standing at ₹44,185 Crores.
What is the current share price of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd’s shares are currently trading at ₹1,566 as of August 17th, 2024.
What is the share price target for Glenmark Pharmaceuticals Ltd in 2025?
Looking ahead, the share price is expected to range between ₹1,305.85 to ₹1,994.11 by 2025.
What is the share price target for Glenmark Pharmaceuticals Ltd in 2030?
The long-term outlook is optimistic, with a projected range of ₹3,309.25 to ₹5,141.93.
Also Read
- PNB Housing Finance Ltd Share Price Target 2024, 2025 to 2030
- Himadri Speciality Chemical Ltd Share Price Target 2024, 2025 to 2030
- H.G. Infra Engineering Limited Share Price Target 2024, 2025 to 2030
Conclusion
In summary, Glenmark Pharmaceuticals Ltd’s Q1 FY25 results show a notable recovery in its financial performance. The company’s net profit more than doubled, largely due to a significant rise in profit before exceptional items and taxes. Revenue increased by 6.9%, and EBITDA saw a substantial rise of 34.5%, indicating enhanced operational efficiency. The strong growth in formulation sales in India further highlights Glenmark’s robust market presence. These results reflect the company’s effective strategies and resilience, setting it up for ongoing success in the upcoming quarters.
Leave a Reply